NCT04902040 2026-03-18
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
Clinical Trials
70 trialsNCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT02316548 2025-11-20
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
Phase 2 Terminated
NCT03747419 2025-10-31
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01495676 2025-10-10
GETUGV04
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Terminated
NCT05819827 2025-04-27
Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
Mayo Clinic
Terminated
NCT02122172 2025-04-25
Afatinib in Advanced Refractory Urothelial Cancer
University of Chicago
Phase 2 Terminated
NCT02053662 2025-03-21
Biomarker Identification for Bladder Cancer Patients
Ohio State University Comprehensive Cancer Center
Terminated
NCT03134027 2024-07-18
Immune PDX
Duke University
Terminated
NCT04806334 2024-04-18
Radiogenomics of Muscle Invasive Bladder Cancer
Cedars-Sinai Medical Center
Phase NA Terminated
NCT04430036 2024-04-04
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase 2 Terminated
NCT04779489 2024-02-06
CIRTiN-BC
University of Texas Southwestern Medical Center
Phase NA Terminated
NCT02887248 2023-12-05
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT01215136 2023-11-24
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04066894 2023-08-14
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02612194 2022-11-03
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02735512 2022-08-10
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
University of Southern California
Terminated
NCT02901548 2022-07-29
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01732107 2022-07-11
Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03718741 2022-05-09
Bladder-Aid
Istituto Clinico Humanitas
Phase NA Terminated
NCT03324282 2022-05-03
GCISAVE
University Hospital, Bordeaux
Phase 2 Terminated
NCT02164942 2022-04-26
LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer
Wake Forest University Health Sciences
Terminated
NCT03266900 2022-04-20
RESECT
University Health Network, Toronto
Phase EARLY_PHASE1 Terminated
NCT03549650 2022-03-04
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Terminated
NCT01954173 2022-03-02
Adjuvant Radiation for High Risk Bladder Cancer
Emory University
Phase NA Terminated
NCT03389438 2021-12-01
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
Beijing Huanxing Cancer Hospital
Phase 2 Terminated
NCT02767921 2021-11-24
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
University of Southern California
Phase 1 Terminated
NCT04273724 2021-10-18
Early Intervention for Impairments Identified During Comprehensive Geriatric Assessment in Patients With Bladder Cancer
UNC Lineberger Comprehensive Cancer Center
Phase NA Terminated
NCT04579133 2021-06-16
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
Phase 2 Terminated
NCT03498196 2020-08-24
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Baylor College of Medicine
Phase 1/2 Terminated
NCT00350688 2020-04-17
Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy
Ottawa Hospital Research Institute
Phase NA Terminated
NCT03986398 2020-04-08
Cranberry
Hopital Foch
Phase NA Terminated
NCT03007719 2020-01-21
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
University of California, San Francisco
Phase 2 Terminated
NCT02365207 2019-11-05
Intravesical BCG Administration to Patients With Invasive Bladder Cancer
The University of Texas Health Science Center at San Antonio
Phase NA Terminated
NCT01611662 2019-07-29
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
Fox Chase Cancer Center
Phase 2 Terminated
NCT02202044 2019-06-14
Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection
University of Colorado, Denver
Phase NA Terminated
NCT01118351 2019-05-01
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01342172 2019-04-23
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated
NCT02350543 2019-04-08
Peri-operative Aspirin Continuation Versus Discontinuation
Rabin Medical Center
Phase 4 Terminated
NCT02900248 2019-04-02
N1
CureOne
Terminated
NCT02560038 2018-11-28
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT02145390 2018-08-28
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
University of Miami
Phase NA Terminated
NCT02700724 2018-08-13
Observation Versus Immediate Surgery of Low Risk Bladder Cancer
Vanderbilt University Medical Center
Phase NA Terminated
NCT00089128 2018-07-12
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Medical University of South Carolina
Phase 2 Terminated
NCT03106610 2018-05-24
Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT01331824 2018-04-23
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT01261299 2018-01-09
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
University of California, Davis
Phase EARLY_PHASE1 Terminated
NCT01622660 2017-08-22
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT02027649 2017-07-21
Detection of K14 in Bladder Cancer With a Non Invasive Technique
Corporacion Parc Tauli
Terminated
NCT01042795 2017-06-28
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
Phase 2 Terminated